| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenue | 28,353 | 379* | 1,941 | NaN |
| Cost of revenue | 22,603 | 1,379* | 1,057 | NaN |
| Gross margin | 5,750 | -1,000 | 884 | NaN |
| General and administrative (including stock based compensation of 13,406 and 14,131,250, respectively) | 1,020,457 | 1,655,199 | 512,993 | 395,692 |
| Research and development | 296,723 | 100,035 | 207,899 | 352,887 |
| Sales and marketing | 334,739 | 93,190 | 425,489 | 51,311 |
| Total operating expenses | 1,651,919 | 1,848,424 | 1,146,381 | 799,890 |
| Loss from operations | -1,646,169 | -1,849,424 | -1,145,497 | NaN |
| Interest income | 5,009 | NaN | NaN | NaN |
| Interest expense | 1,595,315 | 7,032,907.5* | 1,480,058 | 527,893 |
| Initial recognition of forward purchase liability | NaN | -23,765.5* | NaN | NaN |
| Gain on extinguishment of debt | NaN | 728,218* | NaN | -364,109 |
| Change in fair value of derivative liabilities and convertible notes | 251,807 | 3,470,145 | 775,062 | -289,401 |
| Loss on extinguishment of debt | 238,224 | NaN | NaN | NaN |
| Total other expense, net | -1,576,723 | -2,858,310 | -704,996 | -1,181,403 |
| Loss before provision for income taxes | -3,222,892 | -4,707,734 | NaN | NaN |
| Net loss | -3,222,892 | -4,707,734 | -1,850,493 | -1,981,293 |
| Basic EPS | -20.57 | NaN | -0.04 | NaN |
| Diluted EPS | -20.57 | 0.101 | -0.04 | NaN |
| Basic Average Shares | 156,685 | -46,536,058 | 49,525,970 | NaN |
| Diluted Average Shares | 156,685 | -46,536,058 | 49,525,970 | NaN |
Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP)